9月25日，Revolution Medicines盘中上涨5.09%，报200.44美元/股，成交额5.38亿美元。
消息面上，近期多重利好持续发酵。美国银行证券于9月21日将公司目标价从225美元大幅上调至265美元，维持买入评级；此前摩根士丹利首次覆盖即给予增持评级及255美元目标价，预计公司药物组合峰值风险调整后销售额可达约120亿美元。9月15日，公司核心产品Rasonque联合化疗获FDA突破性疗法认定，用于一线转移性胰腺癌治疗，进一步拓宽商业化前景。Rasonque于8月底获FDA批准上市，30天疗程定价39,800美元，RBC预计该药将实现快速放量，预估全年美国销售额达2.49亿美元。
Revolution Medicines成立于2014年，是一家精准肿瘤学公司，专注于开发靶向RAS成瘾癌症的创新疗法，拥有深厚的化学生物学和药物发现能力。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.